(Q39976030)

English

Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

retracted paper

1 reference

Retraction Watch

29 December 2023

https://doi.org/10.1097/JTO.0b013e3181753b24

https://retractionwatch.com/?s=Roman+Perez-Soler

Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

1 reference

based on heuristic

inferred from title

author name string

Tianhong Li

1

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Yi-He Ling

2

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Roman Perez-Soler

3

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

publication date

1 June 2008

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Journal of Thoracic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

643-647

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Erlotinib in previously treated non-small-cell lung cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1097/JTO.0B013E3181753B24

The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1097/JTO.0B013E3181753B24

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1097/JTO.0B013E3181753B24

An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1097/JTO.0B013E3181753B24

Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1097/JTO.0B013E3181753B24

Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1097/JTO.0B013E3181753B24

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1097/JTO.0B013E3181753B24

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1097/JTO.0B013E3181753B24

Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1097/JTO.0B013E3181753B24

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1097/JTO.0B013E3181753B24

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1097/JTO.0B013E3181753B24

Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1097/JTO.0B013E3181753B24

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1097/JTO.0B013E3181753B24

Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1097/JTO.0B013E3181753B24

Identifiers

10.1097/JTO.0B013E3181753B24

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39976030&oldid=2249131029"